Patents by Inventor Changshou Gao

Changshou Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110033378
    Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.
    Type: Application
    Filed: January 16, 2009
    Publication date: February 10, 2011
    Applicant: Medlmmune, LLC.
    Inventors: Nazzareno Dimasi, Changshou Gao, Herren Wu
  • Publication number: 20100331208
    Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Application
    Filed: July 15, 2010
    Publication date: December 30, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Changshou GAO, Herren WU
  • Publication number: 20100233173
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 16, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI
  • Patent number: 7790655
    Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: September 7, 2010
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Herren Wu
  • Publication number: 20100203045
    Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.
    Type: Application
    Filed: December 4, 2009
    Publication date: August 12, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren Wu, Changshou Gao
  • Publication number: 20100061987
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Application
    Filed: August 3, 2009
    Publication date: March 11, 2010
    Applicant: MedImmune, LLC
    Inventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
  • Patent number: 7659374
    Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: February 9, 2010
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Changshou Gao
  • Patent number: 7585504
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: September 8, 2009
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
  • Publication number: 20090169546
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Application
    Filed: November 27, 2006
    Publication date: July 2, 2009
    Applicants: MEDIMMUNE, LLC, CRITICAL THERAPEUTICS
    Inventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
  • Publication number: 20090155275
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: July 30, 2008
    Publication date: June 18, 2009
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI
  • Publication number: 20070111260
    Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Application
    Filed: October 13, 2006
    Publication date: May 17, 2007
    Applicant: MEDIMMUNE, INC.
    Inventors: Changshou Gao, Herren Wu
  • Patent number: 7078166
    Abstract: The invention describes the display of exogenous polypeptides on filamentous phage using a fusion between the exogenous polypeptide and phage pVII or pIX proteins. In particular, phage particles and phagemid vectors are described for expression and display of heterodimeric proteins such as antibody Fv heterodimers in combinatorial libraries, and uses thereof.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: July 18, 2006
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Peter Wirsching, Richard A. Lerner, Changshou Gao
  • Publication number: 20060099207
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Application
    Filed: October 21, 2005
    Publication date: May 11, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, Christian Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
  • Publication number: 20060094062
    Abstract: The present invention relates to a method for identification and isolation of binding molecules having a selective affinity for a ligand. More specifically, this invention provides a process for the ultra high throughput screening of binding molecules from expression libraries containing billions of independent clones without the biases and limitations of other high throughput screening methods such as panning. Additionally, the present invention provides a method for the production of expression libraries essentially free of clones encoding non-functional molecules.
    Type: Application
    Filed: October 31, 2005
    Publication date: May 4, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, Changshou Gao
  • Publication number: 20060040325
    Abstract: The present invention relates to novel Fc variants of antibodies that immunospecifically binds to Integrin ?v?3. The Fc variants comprise a variable region that immunospecifically binds to Integrin ?v?3 and a Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants of an antibody that immunospecifically binds to Integrin ?v?3, particularly for therapeutic purposes.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 23, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, Changshou Gao
  • Publication number: 20060039904
    Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 23, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, Changshou Gao
  • Publication number: 20030186322
    Abstract: The invention describes the display of exogenous polypeptides on filamentous phage using a fusion between the exogenous polypeptide and phage pVII or pIX proteins. In particular, phage particles and phagemid vectors are described for expression and display of heterodimeric proteins such a antibody Fv heterodimers in combinatorial libraries, and uses thereof.
    Type: Application
    Filed: August 14, 2002
    Publication date: October 2, 2003
    Applicant: The Scripps Research Institute
    Inventors: Kim D. Janda, Peter Wirsching, Richard A. Lerner, Changshou Gao
  • Patent number: 6472147
    Abstract: The invention describes the display of exogenous polypeptides on filamentous phage using a fusion between the exogenous polypeptide and phage pVII or pIX proteins. In particular, phage particles and phagemid vectors are described for expression and display of heterodimeric proteins such a antibody Fv heterodimers in combinatorial libraries, and uses thereof.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: October 29, 2002
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Peter Wirsching, Richard A. Lerner, Changshou Gao